Applied Therapeutics Inc (NASDAQ:APLT) announced sorbitol reduction data from the ongoing global Phase 3 INSPIRE trial of oral AT-007 in approximately…
Median OS was 42.1 months for the LYNPARZA plus abi/pred arm versus 34.7 months for the placebo plus abi/pred arm, representing a 7.4-month absolute difference in median OS versus a standard of care
The submission will allow Intelligent Bio Solutions to determine the most suitable FDA regulatory pathway as part of the Company's strategy for expansion into the U.S. market.
The Intelligent Fingerprinting
The arm is part of the I-SPY 2 Endocrine Optimization Platform (EOP), which is focused on patients with clinically high-risk (stage 2/3) estrogen receptor-positive (ER+)/HER2- breast cancer, but the molecularly
To date, the BE-Smart test has been tested on over 200 human samples by mProbe Inc, a precision health and medicine company utilizing clinical proteomics in the oncology space, and has shown greater
Cantor Fitzgerald initiated coverage on Immunovant Inc (NASDAQ:IMVT) with an Overweight rating and a price target of $30. The company’s pipeline includes…
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) received written notice from Janssen, a unit of Johnson & Johnson (NYSE:JNJ), to terminate their rights to JNJ-75220795, now called…
This final analysis demonstrated a statistically significant and clinically meaningful improvement in overall survival in nasopharyngeal carcinoma patients treated with toripalimab plus chemotherapy compared to